Do analysts believe Catalent (USA Stocks:CTLT) will continue to gain?

CTLT Stock  USD 64.27  1.63  2.60%   
Catalent is scheduled to announce its earnings today. The stock is currently undergoing above-average trading activities. As many millenniums are getting excited about pharmaceuticals space, it is only fair to review the feasibility of shorting Catalent. We will evaluate why we are still optimistic in anticipation of a recovery.
Published over a month ago
View all stories for Catalent | View All Stories
Macroaxis uses a strict editorial review process to publish our stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Vlad Skutelnik

The company currently holds 4.17 B in liabilities with Debt to Equity (D/E) ratio of 0.9, which is about average as compared to similar companies.
What is the right price you would pay to acquire a share of Catalent? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated.
Please read more on our stock advisor page.

What is happening with Catalent this year

Annual and quarterly reports issued by Catalent are formal financial statements that are published yearly and quarterly and sent to Catalent stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Catalent often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How does Catalent utilize its cash?

To perform a cash flow analysis of Catalent, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Catalent is receiving and how much cash it distributes out in a given period. The Catalent cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Catalent Net Cash Flow from Operations is comparatively stable at the moment as compared to the past year. Catalent reported Net Cash Flow from Operations of 504.85 Million in 2022

Is Catalent a risky opportunity?

Let's check the volatility. Catalent is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Catalent (USA Stocks:CTLT) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. acquiring a share of a Catalent stock makes you a part-owner of that company.

Catalent Current Consensus

Here is the newest trade recommendation based on an ongoing consensus estimate among financial analysis covering Catalent. The Catalent consensus assessment is calculated by taking the average estimates from all of the analysts covering Catalent

Strong Buy
Strong Buy872.73
Strong Sell00.0

Are Catalent technical ratios showing a correction?

The mean deviation is down to 3.01 as of today. Catalent shows above-average downside volatility for the selected time horizon. We advise investors to inspect Catalent further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Catalent future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Catalent's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Catalent's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Perspective on Catalent

Whereas other companies under the drug manufacturers—specialty & generic industry are still a bit expensive, Catalent may offer a potential longer-term growth to private investors. With an optimistic outlook on your 90 days horizon, it may be a good time to take over new shares of Catalent or increase your existing holdings in the Stock as it seems the potential growth has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Catalent.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Catalent. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to